Clinical Trial: 21469

Trial Status: Open
Disease Type: Multiple Hematologic
Trial ID 21469
Sponsor ID LOTIS 9

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)

Principal Investigator
Mitul Gandhi, MD

Locations

Fairfax Office

Arlington Office

Gainesville Office

Learn More About This Trial
Other Relevant Trials
Trial ID 22087
Sponsor ID H3B-8800-G000-101

“An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101)”

Principal Investigator
Mitul Gandhi, MD
Trial ID 21328
Sponsor ID KCP-8602-801

“A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)”

Principal Investigator
Mitul Gandhi, MD